Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineeredTM monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors.

Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineeredTM monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineeredTM monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Abstract Text:

S Goel,R J Bauer,K Desai,A Bulgaru,T Iqbal,B-K Strachan,G Kim,A Kaubisch,G F Vanhove,G Goldberg,S Mani,S Goel,R J Bauer,K Desai,A Bulgaru,T Iqbal,B-K Strachan,G Kim,A Kaubisch,G F Vanhove,G Goldberg,S Mani,S Goel,R J Bauer,K Desai,A Bulgaru,T Iqbal,B-K Strachan,G Kim,A Kaubisch,G F Vanhove,G Goldberg,S Mani,

BACKGROUND: ING-1 is a high-affinity, human engineeredtrade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas and is an attractive target for immunotherapy. METHODS: ING-1 was administered subcutaneously weekly at doses between 0.1 and 2 mg/kg/week. Pharmacokinetic samples were drawn during weeks 1 and 6. RESULTS: Fourteen patients with advanced refractory cancer received a median of 6 (range 1-9) doses of ING-1. At 1 mg/kg, a 62-year-old man with colon cancer developed reversible grade 3 pancreatitis after the third dose. His plasma ING-1 levels were similar to the other two patients dosed at 1 mg/kg. Two patients dosed at 0.6 mg/kg experienced stable disease at 6 weeks. Peak drug levels increased with dose and time, suggesting drug accumulation with repeated dosing. Low human anti-human antibody response was noted in three of the 13 patients assessed and was directed towards the variable region of ING-1. CONCLUSIONS: Weekly ING-1 administered subcutaneously was well tolerated at 0.6 mg/kg/week and further experience at this dose is warranted to demonstrate safety. The risk of pancreatitis and the marginal anti-tumor effect may preclude further monotherapy studies; however, combination studies with chemotherapy are warranted.

Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineeredTM monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Publishing Authors By Initials

S Goel,RJ Bauer,K Desai,A Bulgaru,T Iqbal,BK Strachan,G Kim,A Kaubisch,GF Vanhove,G Goldberg,S Mani,S Goel,RJ Bauer,K Desai,A Bulgaru,T Iqbal,BK Strachan,G Kim,A Kaubisch,GF Vanhove,G Goldberg,S Mani,S Goel,RJ Bauer,K Desai,A Bulgaru,T Iqbal,BK Strachan,G Kim,A Kaubisch,GF Vanhove,G Goldberg,S Mani,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineeredTM monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Annals of oncology : official journal of the Europ

VOLUME: 18

Page Numbers: 1704-7

Journal Abbreviation: Ann. Oncol.

ISSN: 0923-7534

DAY: 9

MONTH: 08

YEAR: 2007

Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineeredTM monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9007735

Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineeredTM monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineeredTM monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineeredTM monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors.

AFFILIATION: Albert Einstein Cancer Center.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Ann Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineeredTM monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors Related Publications

• A conceptual model of people's approach to sanitation.
• A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.
• A review of the clinical significance of tissue hypoxia measurements in lower extremity wound management.
• Agranulocytosis induced by nonchemotherapy drugs.
• Arteriographic evaluation of the femoral bifurcation value of the ipsilateral anterior oblique projection.
• Base-mediated reaction of hydrazones and nitroolefins with a reversed regioselectivity: a novel synthesis of 1,3,4-trisubstituted pyrazoles.
• Carcinoma of the tail of the pancreas: an unusual CT appearance.
• Complications of catheter cerebral arteriography: analysis of 5,000 procedures. I. Criteria and incidence.
• Computer-assisted radiology management systems: principles derived from hard experience.
• GAP-43 is key to mitotic spindle control and centrosome-based polarization in neurons.
• Health issues in the Arab American community. Summary report: HIV/AIDS in the Middle East and North Africa.
• Hope for Tamil heads.
• Kidney business as usual.
• Mild radioiodination of insulin with dichloramine-T.
• Molecular detection and antimicrobial resistance of diarrheagenic Escherichia coli strains isolated from diarrheal cases.
• Neurospheres derived from human embryoid bodies treated with retinoic Acid show an increase in nestin and ngn2 expression that correlates with the proportion of tyrosine hydroxylase-positive cells.
• Outcome measurements in wound healing are not inclusive: a way forward.
• Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineeredTM monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors.
• Photosynthesis in the ears of five varieties of wheat.
• RAPORT radiology system: results of clinical trials.
• Reference range of thyroid hormones in normal Indian school-age children.
• Regioselective synthesis of 1,3,5-tri- and 1,3,4,5-tetrasubstituted pyrazoles from N-arylhydrazones and nitroolefins.
• Role of nitric oxide in the gastro-protective effect of lithium.
• Shoulder MR arthrography: which patient group benefits most?
• Surgical reconstruction of the hand with triple nerve palsy.
• The comparison of the diuretic and natriuretic efficacy of continuous and bolus intravenous furosemide in patients with chronic kidney disease.
• The cradle baby scheme.
• The role of integrated education for blind children.
• The significance of measurements in wound healing: where do we go from here?
• [History of hygiene. Continuity and changes of hygienic ideas from antiquity to the 19th century]